Erythropoietin after a century of research: younger than ever

@article{Jelkmann2007ErythropoietinAA,
  title={Erythropoietin after a century of research: younger than ever},
  author={Wolfgang Jelkmann},
  journal={European Journal of Haematology},
  year={2007},
  volume={78}
}
  • W. Jelkmann
  • Published 1 March 2007
  • Biology, Medicine
  • European Journal of Haematology
In the light of the enthusiasm regarding the use of recombinant human erythropoietin (Epo) and its analogues for treatment of the anaemias of chronic renal failure and malignancies it is worth remembering that today's success has been based on a century of laborious research. The concept of the humoral regulation of haematopoiesis was first formulated in 1906. The term ‘erythropoietin’ for the erythropoiesis‐stimulating hormone was introduced in 1948. Native human Epo was isolated in 1977 and… 
[Erythropoietin - state of science].
TLDR
After a century of research and medical use, erythropoietin (EPO) has more therapeutic approaches than ever in history and its analogues are mainly used for treatment of the anaemias of chronic renal failure and malignancies.
Regulation of erythropoietin production and recent trends in anaemia therapy
TLDR
The regulation of erythropoietin production and its functions, as well as treatment approach for anaemia of chronic kidney disease, with particular focus on new therapies are reviewed.
Erythropoietin use and abuse
TLDR
EPO has been abused by athletes participating in endurance sports and detecting this has proved to be a challenge, so its efficacy in stimulating erythropoiesis is dose dependent and differs according to the patient's disease and nutritional status.
The Therapeutic Potential of Erythropoiesis-Stimulating Agents for Tissue Protection: A Tale of Two Receptors
  • M. Brines
  • Biology, Medicine
    Blood Purification
  • 2010
TLDR
To circumvent these undesirable effects, the EPO molecule has been successfully altered to selectively eliminate erythropoietic and prothrombotic potencies, while preserving tissue-protective activities.
Erythropoietin and co.: intrinsic structure and functional disorder.
TLDR
The goal of this article is to evaluate the roles of intrinsic disorder in the functions of Epo and its primary interactors, EpoR, βCR, and HIF-1α.
Case Study: Immunogenicity of rhEPO
Erythropoietin is an endogenous growth factor that is required for erythropoiesis. The hormone consists of a single acidic polypeptide chain of 165 amino acids and three N-linked and one O-linked
Regulation of erythropoietin production
  • W. Jelkmann
  • Biology, Medicine
    The Journal of physiology
  • 2011
TLDR
The hormone erythropoietin (Epo) maintains red blood cell mass by promoting the survival, proliferation and differentiation of erythrocytic progenitors and recombinant analogues can substitute for the hormone.
...
...

References

SHOWING 1-10 OF 435 REFERENCES
Erythropoietin: A Somewhat Personal History
TLDR
A personal account of the experience that spans the period when epo was considered to be a laboratory curiosity to the present, and has been a time of important advances in the study of the molecular and cellular biology of epo, its receptor, and of erythropoiesis.
New agents that stimulate erythropoiesis.
TLDR
The hypoxia inducible transcription factor (HIF) can be pharmacologically induced by oral agents, resulting in enhanced expression not only of endogenous Epo but also of other genes important in the regulation of erythropoiesis.
Beneficial and ominous aspects of the pleiotropic action of erythropoietin
TLDR
The role of Epo as a myocardial protectant is at the focus of present research and careful studies are required to fully exclude that recombinant human Epo (rHuEpo) promotes tumor growth.
Erythropoietin Biology in Cancer
TLDR
Erythropoietin (Epo) has long been known to be the principal hematopoietic growth factor that regulates cellular proliferation and differentiation along the erythroid lineage and potential effects of Epo on tumor microenvironment and angiogenesis are consistent with a complex biology for Epo-EpoR signaling in cancer that requires further research.
CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
TLDR
Continuous Erythropoietin Receptor Activator (CERA), a third-generation molecule, incorporating a large polymer chain, has been developed and has an elimination half-life in humans that is considerably longer than the half- life of either epoetin or darbepoetIn alfa.
Effects of erythropoietin on brain function.
  • W. Jelkmann
  • Biology, Medicine
    Current pharmaceutical biotechnology
  • 2005
TLDR
The recent advances in understanding the molecular mechanisms by which the hypoxia-inducible transcription factor 1 (HIF-1) regulates O(2)-dependent genes, including the EPO gene in brain are summarised.
Physiology and function of the erythropoietin receptor
TLDR
The three-dimensional structure of the EPOR has been determined, and a biologically active 20 amino acid peptide has been shown to cause dimerization of the extracellular domain of EPOR.
The prolonged half-lives of new erythropoietin derivatives via peptide addition.
Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
TLDR
Recombinant human erythropoietin (epoetin alfa) is undergoing evaluation with promising results in a variety of new clinical settings, including anemia associated with congestive heart failure, ribavirin-interferon alfa treatment of hepatitis C virus infection, and critical illness.
Isolation and characterization of genomic and cDNA clones of human erythropoietin
TLDR
The cloning of the human erythropoietin gene and the expression of an erythrocytes cDNA clone in a transient mammalian expression system to yield a secreted product with biological activity are described.
...
...